ABC-02
The 2010 UK trial that gave bile duct cancer its first standard chemotherapy.
OS 11.7 vs 8.1 months (HR 0.64); PFS 8.0 vs 5.0 months. Remained the control arm for every subsequent first-line trial for over a decade.
- Median 11.7 vs 8.1 months with Gemcitabine + cisplatin compared with Gemcitabine; about 3.6 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 36 percent lower chance of the event at any given time (hazard ratio 0.64, likely range 0.52 to 0.8).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Locally advanced or metastatic biliary tract cancer: gemcitabine + cisplatin vs gemcitabine. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
410 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Gemcitabine + cisplatin | 204 | 11.7 months | 0.64 (0.52–0.8) | <0.001 | — |
| Gemcitabine | 206 | 8.1 months |
Pages like this
not linked directly; found by shared links- TrialHERIZON-BTC-302
Shares Gemcitabine + cisplatin, Biliary tract cancer (cholangiocarcinoma).
- TrialBILCAP
Shares Biliary tract cancer (cholangiocarcinoma), Cancer Research UK.
- TrialKEYNOTE-966
Shares Gemcitabine + cisplatin, Biliary tract cancer (cholangiocarcinoma).
- TrialTOPAZ-1
Shares Gemcitabine + cisplatin, Biliary tract cancer (cholangiocarcinoma).
- PairingGemcitabine-cisplatin + PD-(L)1 blockade in biliary cancer
Shares Gemcitabine + cisplatin, Biliary tract cancer (cholangiocarcinoma).
- PersonDo-Youn Oh
Shares Gemcitabine + cisplatin, Biliary tract cancer (cholangiocarcinoma).
- IdeaOne standing umbrella trial for all rare cancers in a country
Shares Biliary tract cancer (cholangiocarcinoma), Cancer Research UK.